Analytical Data
-
基因名
NIP30
- Application
-
别名
C16orf94; CDA018; CDA10; F192A_HUMAN; Fam192a; LOC80011; NEFA interacting nuclear protein; NEFA-interacting nuclear protein NIP30; NIP 30; NIP30; Protein FAM192A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9GZU8
-
表达区间
1-254 aa
-
氨基酸序列
MDGGDDGNLI IKKRFVSEAE LDERRKRRQE EWEKVRKPED PEECPEEVYD PRSLYERLQE QKDRKQQEYE EQFKFKNMVR GLDEDETNFL DEVSRQQELI EKQRREEELK ELKEYRNNLK KVGISQENKK EVEKKLTVKP IETKNKFSQA KLLAGAVKHK SSESGNSVKR LKPDPEPDDK NQEPSSCKSL GNTSLSGPSI HCPSAAVCIG ILPGLGAYSG SSDSESSSDS EGTINATGKI VSSIFRTNTF LEAP
-
分子量
28.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NIP30, a member of the NIP (Nuclear Import Protein) family, has emerged as a significant focus in the field of molecular biology due to its role in cellular processes such as nuclear transport and signal transduction. Understanding NIP30 is crucial because it is implicated in various physiological and pathological conditions, including cancer and neurodegenerative disorders. Recent studies have highlighted its involvement in the regulation of gene expression and cellular stress responses, prompting researchers to explore its potential as a therapeutic target. Moreover, the recombinant production of NIP30 protein has enabled detailed biochemical characterization, facilitating the study of its structure-function relationships. Enhancements in protein engineering techniques have further allowed for modifications that can elucidate its mechanisms of action. As researchers uncover the complexities of NIP30's interactions within the cell, the potential applications in targeted therapies and drug development continue to expand. Overall, the study of NIP30 is paving the way for novel insights into fundamental biological processes and therapeutic innovations.
